The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

This study reveals that neutrophil extracellular traps (NETs) drive macrophage-derived chemokine production (CXCL9/10/11) to promote CD8+ T cell ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...

Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the most undervalued US stocks according to analysts. On June 20, Lantheus ...

A new PET/CT imaging technique that visualizes activated fibroblasts in the heart muscle enables early detection of ...